Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Daver NG"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-8 z 8
    Tytuł:
    Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Autorzy:
    Daver NG; University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. .
    Iqbal S; Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA, 94404, USA.
    Renard C; Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA, 94404, USA.
    Chan RJ; Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA, 94404, USA.
    Hasegawa K; Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA, 94404, USA.
    Hu H; Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA, 94404, USA.
    Tse P; McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
    Yan J; McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
    Zoratti MJ; McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
    Xie F; McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
    Ramsingh G; Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA, 94404, USA.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2023 Mar 06; Vol. 16 (1), pp. 19. Date of Electronic Publication: 2023 Mar 06.
    Typ publikacji:
    Meta-Analysis; Systematic Review; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Myeloid, Acute*/drug therapy
    Leukemia, Myeloid, Acute*/genetics
    Humans ; Retrospective Studies ; Treatment Outcome ; Progression-Free Survival ; Mutation ; Tumor Suppressor Protein p53/genetics ; Observational Studies as Topic
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Autorzy:
    Venugopal S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Ning J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Rausch CR; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (14), pp. 3501-3505. Date of Electronic Publication: 2021 Sep 03.
    Typ publikacji:
    Letter; Research Support, N.I.H., Extramural
    MeSH Terms:
    Bridged Bicyclo Compounds, Heterocyclic*/adverse effects
    Leukemia, Myeloid, Acute*/diagnosis
    Leukemia, Myeloid, Acute*/drug therapy
    Leukemia, Myeloid, Acute*/genetics
    Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/therapeutic use ; Cytogenetic Analysis ; Decitabine/therapeutic use ; Humans ; Prognosis ; Sulfonamides
    Raport
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
    Autorzy:
    Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Alfayez M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Pierce SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Ghayas I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Assi R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Alotaibi AS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA. .
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2021 Feb 23; Vol. 14 (1), pp. 34. Date of Electronic Publication: 2021 Feb 23.
    Typ publikacji:
    Published Erratum
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
    Autorzy:
    Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Alfayez M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Pierce SA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Ghayas I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Assi R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Alotaibi AS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA.
    Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit FC4.2012, Houston, TX, 77030, USA. .
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2020 Oct 08; Vol. 13 (1), pp. 132. Date of Electronic Publication: 2020 Oct 08.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Myeloid, Acute/*drug therapy
    Protein Kinase Inhibitors/*therapeutic use
    fms-Like Tyrosine Kinase 3/*antagonists & inhibitors
    Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Mutation/drug effects ; Retrospective Studies ; Treatment Outcome ; Young Adult ; fms-Like Tyrosine Kinase 3/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
    Autorzy:
    Rafei H; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Sinicrope KD; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kamiya-Matsuoka C; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Mehta RS; Departement of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Naqvi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (13), pp. 3292-3295. Date of Electronic Publication: 2019 Jun 27.
    Typ publikacji:
    Case Reports; Letter
    MeSH Terms:
    Fusion Proteins, bcr-abl/*antagonists & inhibitors
    Intervertebral Disc Degeneration/*chemically induced
    Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
    Myelitis, Transverse/*chemically induced
    Optic Neuritis/*chemically induced
    Protein Kinase Inhibitors/*adverse effects
    Aged ; Dasatinib/adverse effects ; Female ; Fusion Proteins, bcr-abl/genetics ; Humans ; Imatinib Mesylate/adverse effects ; Intervertebral Disc Degeneration/diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Male ; Myelitis, Transverse/diagnosis ; Optic Neuritis/diagnosis
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
    Autorzy:
    Bose P; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Swaminathan M; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Pemmaraju N; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Ferrajoli A; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Jabbour EJ; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Daver NG; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    DiNardo CD; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Alvarado Y; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Yilmaz M; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Huynh-Lu J; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Qiao W; b Department of Biostatistics , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Wang X; b Department of Biostatistics , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Matamoros A; c Division of Diagnostic Radiology , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Zhou L; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Pierce S; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Schroeder KD; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Kantarjian HM; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Verstovsek S; a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Jul; Vol. 60 (7), pp. 1767-1774. Date of Electronic Publication: 2019 Jan 11.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Primary Myelofibrosis/*drug therapy
    Aged ; Benzimidazoles/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Nitriles ; Primary Myelofibrosis/pathology ; Prognosis ; Pyrazoles/administration & dosage ; Pyrimidines ; Survival Rate
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Autorzy:
    Short NJ; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Kantarjian H; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Ravandi F; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Huang X; b Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Xiao L; b Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Garcia-Manero G; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Plunkett W; c Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Gandhi V; c Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Sasaki K; d Division of Cancer Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Pemmaraju N; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Daver NG; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Borthakur G; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Jain N; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Konopleva M; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Estrov Z; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Kadia TM; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Wierda WG; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    DiNardo CD; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Brandt M; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    O'Brien SM; c Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Cortes JE; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
    Jabbour E; a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.; e Chao Family Comprehensive Cancer Center , University of California Irvine , Orange , CA , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Apr; Vol. 59 (4), pp. 813-820. Date of Electronic Publication: 2017 Jul 18.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Clofarabine/*therapeutic use
    Cytarabine/*therapeutic use
    Idarubicin/*therapeutic use
    Leukemia, Myeloid, Acute/*drug therapy
    Vidarabine/*analogs & derivatives
    Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bone Marrow/pathology ; Clofarabine/pharmacology ; Cytarabine/pharmacology ; Drug Resistance, Neoplasm ; Humans ; Idarubicin/pharmacology ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Middle Aged ; Neoplasm Recurrence, Local ; Progression-Free Survival ; Remission Induction/methods ; Survival Rate ; Treatment Outcome ; Vidarabine/pharmacology ; Vidarabine/therapeutic use ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-8 z 8

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies